Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 詳細を表示
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet...
PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 3.1007751938 | 2.58 | 2.79 | 2.53 | 35605 | 2.63421195 | CS |
4 | 0.24 | 9.9173553719 | 2.42 | 3.56 | 2.42 | 163126 | 2.95779665 | CS |
12 | -1.1944 | -30.9879618099 | 3.8544 | 4.116 | 2.21 | 881067 | 3.39136457 | CS |
26 | -2.42 | -47.6377952756 | 5.08 | 12 | 2.21 | 2216837 | 6.13945278 | CS |
52 | -5.34 | -66.75 | 8 | 12 | 2.21 | 1145759 | 6.1456873 | CS |
156 | -53.5 | -95.2635327635 | 56.16 | 61.76 | 2.21 | 791246 | 10.18968827 | CS |
260 | -53.5 | -95.2635327635 | 56.16 | 61.76 | 2.21 | 791246 | 10.18968827 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約